Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis
NCT04882072 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 15, 2021
- Completion date
- May 25, 2023
- Enrollment
- 14 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.